Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Pharmaceuticals Outlines 2019 Key Milestones
January 6, 2019
Xenon to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting
November 30, 2018
Xenon to Present at the Stifel 2018 Healthcare Conference
November 7, 2018
Xenon Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 6, 2018
Product Pipeline
* Xenon has entered into key regulatory and manufacturing agreements related to XEN007; it is anticipated that a Phase 2 clinical trial could be initiated after receiving regulatory feedback.
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
